{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:12:09Z","timestamp":1777327929706,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["2232010"],"award-info":[{"award-number":["2232010"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22476011"],"award-info":[{"award-number":["22476011"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22276015"],"award-info":[{"award-number":["22276015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21771023"],"award-info":[{"award-number":["21771023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22076013"],"award-info":[{"award-number":["22076013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484470"],"award-info":[{"award-number":["20230484470"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117264","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:30:06Z","timestamp":1736555406000},"page":"117264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Novel technetium-99m-labelled ribociclib isocyanide derivatives for imaging cyclin-dependent kinase 4\/6 (CDK4\/6) expression in cancer"],"prefix":"10.1016","volume":"286","author":[{"given":"Peiwen","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangxing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingna","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dajie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-6483","authenticated-orcid":false,"given":"Junbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2025.117264_bib1","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/mco2.136","article-title":"In vivo visualization of fluorescence reflecting cdk4 activity in a breast cancer mouse model","volume":"3","author":"Gao","year":"2022","journal-title":"Medcomm"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117264_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/1535-7163.MCT-06-0613","article-title":"In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, p276-00","volume":"6","author":"Joshi","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117264_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0092-8674(00)81684-0","article-title":"A long twentieth century of the cell cycle and beyond","volume":"100","author":"Nurse","year":"2000","journal-title":"Cell"},{"issue":"6577","key":"10.1016\/j.ejmech.2025.117264_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1495","article-title":"Cdk4 and cdk6 kinases: from basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117264_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10549-024-07324-8","article-title":"Everolimus plus endocrine therapy beyond cdk4\/6 inhibitors progression for hr+\/her2- advanced breast cancer: a real-world evidence cohort","volume":"206","author":"Sanchez-Bayona","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117264_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by pd 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Fry","year":"2004","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117264_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective cdk4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117264_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1078-0432.CCR-19-3119","article-title":"Cdk4\/6 inhibitor biomarker research: are we barking up the wrong tree?","volume":"26","author":"Anurag","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117264_bib9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1078-0432.CCR-18-1967","article-title":"Arrested developments: cdk4\/6 inhibitor resistance and alterations in the tumor immune microenvironment","volume":"25","author":"Teh","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117264_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to cdk4\/6 inhibition","volume":"37","author":"Alvarez-Fernandez","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117264_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2174\/138955710791384072","article-title":"Cyclin-dependent kinase 4\/6 (cdk4\/6) inhibitors: perspectives in cancer therapy and imaging","volume":"10","author":"Graf","year":"2010","journal-title":"Mini-Rev. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117264_bib12","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1021\/acs.molpharmaceut.3c00216","article-title":"Preparation and evaluation of [(18)f]alf-nota-pbb for pet imaging of cyclin-dependent kinase 4\/6 in tumors","volume":"20","author":"Xiao","year":"2023","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117264_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2967\/jnumed.119.232603","article-title":"Noninvasive pet imaging of cdk4\/6 activation in breast cancer","volume":"61","author":"Ramos","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"47","key":"10.1016\/j.ejmech.2025.117264_bib14","doi-asserted-by":"crossref","first-page":"32253","DOI":"10.1021\/acsomega.1c05073","article-title":"Gallium-68 labeling of the cyclin-dependent kinase 4\/6 inhibitors as positron emission tomography radiotracers for tumor imaging","volume":"6","author":"Liu","year":"2021","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117264_bib15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1021\/acs.analchem.6b03959","article-title":"Radiolabeled rhein as small-molecule necrosis avid agents for imaging of necrotic myocardium","volume":"89","author":"Luo","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2025.117264_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112032","article-title":"Preparation and evaluation of 99mtc-labeled hynic-palbociclib analogs for cyclin-dependent kinase 4\/6-positive tumor imaging","volume":"188","author":"Gan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117264_bib17","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1021\/acs.molpharmaceut.9b00540","article-title":"Synthesis and biological evaluation of novel 99mtc-labeled palbociclib derivatives targeting cyclin-dependent kinase 4\/6 (cdk4\/6) as potential cancer imaging agents","volume":"16","author":"Song","year":"2019","journal-title":"Mol. Pharm."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117264_bib18","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117264_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, erbb2-negative breast cancer that progressed on endocrine therapy-monarch 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117264_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117264_bib21","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3390\/molecules27103062","article-title":"The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker","volume":"27","author":"Holik","year":"2022","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.ejmech.2025.117264_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/chem.202303591","article-title":"Dna-targeted complexes of tc and re for biomedical applications","volume":"30","author":"Palma","year":"2024","journal-title":"Chem.-Eur. J."},{"issue":"5_Supplement","key":"10.1016\/j.ejmech.2025.117264_bib27","doi-asserted-by":"crossref","first-page":"GS1","DOI":"10.1158\/1538-7445.SABCS22-GS1-10","article-title":"Abstract gs1-10: primary results from the randomized phase ii right choice trial of premenopausal patients with aggressive hr+\/her2\u2212 advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy","volume":"83","author":"Lu","year":"2023","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117264_bib28","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304619121","article-title":"Pharmacological modulation of rb1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer","volume":"121","author":"Yu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117264_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188912","article-title":"Immunomodulatory effects of cdk4\/6 inhibitors","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117264_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105659","article-title":"Facile synthesis of c1-substituted beta-carbolines as cdk4 inhibitors for the treatment of cancer","volume":"121","author":"Li","year":"2022","journal-title":"Bioorganic Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117264_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/acs.molpharmaceut.1c00712","article-title":"Preparation and bioevaluation of 99mtc-labeled fap inhibitors as tumor radiotracers to target the fibroblast activation protein","volume":"19","author":"Ruan","year":"2022","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117264_bib31","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/s41467-021-22594-2","article-title":"Mitochondrion-specific dendritic lipopeptide liposomes for targeted sub-cellular delivery","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117264_bib32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nucmedbio.2020.05.005","article-title":"Review on (99m)Tc radiopharmaceuticals with emphasis on new advancements","volume":"92","author":"Duatti","year":"2021","journal-title":"Nucl. Med. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117264_bib33","doi-asserted-by":"crossref","first-page":"6726","DOI":"10.1021\/acs.jmedchem.4c00281","article-title":"Novel cdk19-targeted radiotracers: a potential design strategy to improve the pharmacokinetics and tumor uptake","volume":"67","author":"Dai","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117264_bib23","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1021\/acs.molpharmaceut.8b00415","article-title":"Novel 99mtc-labeled glucose derivative for single photon emission computed tomography: a promising tumor imaging agent","volume":"15","author":"Zhang","year":"2018","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117264_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/ijms25021045","article-title":"Radiosynthesis and bioevaluation of 99mtc-labeled isocyanide ubiquicidin 29-41 derivatives as potential agents for bacterial infection imaging","volume":"25","author":"Jiang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117264_bib25","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1007\/s00259-023-06395-x","article-title":"[99mtc]tc-pentixatec: development, extensive pre-clinical evaluation, and first human experience","volume":"50","author":"Konrad","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T23:42:12Z","timestamp":1740354132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"alternative-id":["S0223523425000297"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117264","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel technetium-99m-labelled ribociclib isocyanide derivatives for imaging cyclin-dependent kinase 4\/6 (CDK4\/6) expression in cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117264"}}